Related Experiment Video
Updated: May 16, 2025

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
Published on: October 9, 2016
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity
Jiajia Zhou1,2, Kole Tison1,2,3,4, Haibin Zhou5
1Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Immune checkpoint blockade (ICB) efficacy relies on dendritic cells. New research reveals STAT3 and STAT5 pathway interplay in dendritic cells is key for ICB success, with STAT3 degraders showing promise in cancer therapy.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Biology
Background:
- Immune checkpoint blockade (ICB) has revolutionized cancer treatment.
- Dendritic cell (DC) function, including antigen presentation and T cell activation, is crucial for immunotherapy efficacy.
- The role of transcription factors in DCs and their impact on ICB outcomes are not fully understood.
Purpose of the Study:
- To investigate the relationship between key transcription factors in dendritic cells and ICB efficacy.
- To elucidate the interplay between STAT3 and STAT5 transcriptional pathways in DCs under ICB.
- To develop and evaluate novel therapeutic strategies targeting STAT3 in DCs for enhanced cancer immunotherapy.
Main Methods:
- Analysis of the STAT3 and STAT5 transcriptional pathways in dendritic cells during ICB.
- Development of PROTAC (proteolysis-targeting chimera) degraders targeting STAT3 (SD-36 and SD-2301).
- Evaluation of STAT3 degrader efficacy in degrading STAT3 in DCs, reprogramming DC transcriptional networks, and treating tumors in mouse models.
Main Results:
- ICB was found to reprogram the interplay between STAT3 and STAT5 pathways in DCs, activating T cell immunity and enabling ICB efficacy.
- STAT3 was identified as a repressor of the JAK2/STAT5 pathway, controlling DC function.
- STAT3 degraders (SD-36 and SD-2301) effectively reduced STAT3 levels in DCs, enhanced DC immunogenicity, and showed efficacy in treating advanced and ICB-resistant tumors in mice without observed toxicity.
Conclusions:
- The crosstalk between STAT3 and STAT5 transcriptional pathways dictates the dendritic cell phenotype within the tumor microenvironment.
- Targeting STAT3 degradation in dendritic cells represents a promising therapeutic approach to overcome resistance and improve the efficacy of cancer immunotherapy.
More Related Videos
11:48Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Related Concept Videos
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
The JAK-STAT Signaling Pathway
Abnormal Proliferation
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...